1. Search Result
Search Result
Results for "

apolipoprotein

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

10

Peptides

2

Natural
Products

44

Recombinant Proteins

1

Isotope-Labeled Compounds

13

Antibodies

10

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147425A

    SLN360 sodium

    Small Interfering RNA (siRNA) Apolipoprotein Cardiovascular Disease
    Zerlasiran sodium is an apolipoprotein A (ApoA) synthesis reducer .
    Zerlasiran sodium
  • HY-132820

    VX-147

    Apolipoprotein Others
    Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease .
    Inaxaplin
  • HY-P2136
    COG1410
    1 Publications Verification

    Apoptosis Neurological Disease Inflammation/Immunology
    COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease .
    COG1410
  • HY-141885

    Apolipoprotein Metabolic Disease
    APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD) .
    APOL1-IN-1
  • HY-103076
    EZ-482
    1 Publications Verification

    Apolipoprotein Neurological Disease
    EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with Kds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas .
    EZ-482
  • HY-P10521

    VEGFR Cancer
    Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .
    Apolipoprotein KV domain (67-77)
  • HY-147425

    SLN360

    Small Interfering RNA (siRNA) Apolipoprotein Cardiovascular Disease
    Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer .
    Zerlasiran
  • HY-153491

    ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx

    Apolipoprotein Cardiovascular Disease
    Olezarsen is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
    Olezarsen
  • HY-P5169

    Amino Acid Derivatives Inflammation/Immunology
    LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
    LVGRQLEEFL (mouse)
  • HY-P5169A

    Amino Acid Derivatives Inflammation/Immunology
    LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
    LVGRQLEEFL (mouse) (TFA)
  • HY-145727A

    ISIS 304801 sodium

    Apolipoprotein Endocrinology
    Volanesorsen sodium is an antisense oligonucleotide thay targes Apolipoprotein C-III (APOC3) mRNA. Volanesorsen sodium is used for the study of familial chylomicronemia syndrome.
    Volanesorsen sodium
  • HY-112798

    Apolipoprotein Neurological Disease
    PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells that could rescue impairments of mitochondrial motility and neurite outgrowth.
    PH-002
  • HY-108764

    ISIS 301012

    Apolipoprotein HCV Metabolic Disease
    Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .
    Mipomersen sodium
  • HY-153491A

    ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium

    Apolipoprotein Cardiovascular Disease
    Olezarsen sodium is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
    Olezarsen sodium
  • HY-P1050

    nAChR Neurological Disease Inflammation/Immunology
    COG 133 is a fragment of Apolipoprotein E (APOE) peptide. COG 133 competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 is also a nAChR antagonist with an IC50 of 445 nM .
    COG 133
  • HY-148647

    ISIS 301012 free base

    Apolipoprotein HCV Infection
    Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .
    Mipomersen
  • HY-W590664

    Endogenous Metabolite Cardiovascular Disease
    C2 Dihydroceramide is a derivative of C2 Ceramide (HY-101180). C2 Dihydroceramide enhances the ABCA1-mediated cholesterol efflux to apolipoprotein A-I (apoA-I) without causing cytotoxicity .
    C2 Dihydroceramide
  • HY-19418

    Others Others
    KRP-101 is a compound that regulates the expression of genes related to lipid metabolism. It is a PPARα agonist that can highly sensitively regulate the expression of genes such as apolipoprotein A-IV, which may be related to lowering serum triglycerides and increasing HDL.
    KRP-101
  • HY-A0143
    Dihomo-γ-linolenic acid
    3 Publications Verification

    DGLA; all-cis-8,11,14-Eicosatrienoic acid

    Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Dihomo-γ-linolenic acid (DGLA) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system .
    Dihomo-γ-linolenic acid
  • HY-P1050A
    COG 133 TFA
    1 Publications Verification

    nAChR Neurological Disease Inflammation/Immunology
    COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM .
    COG 133 TFA
  • HY-145727

    ISIS 304801

    Apolipoprotein Endocrinology
    Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes .
    Volanesorsen
  • HY-A0143A

    DGLA sodium; all-cis-8,11,14-Eicosatrienoic acid sodium

    Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Dihomo-γ-linolenic acid (DGLA; all-cis-8,11,14-Eicosatrienoic acid) sodium is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid (sodium) attenuates atherosclerosis in the apolipoprotein E deficient mouse model system .
    Dihomo-γ-linolenic acid sodium
  • HY-P2136F

    Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Biotin-COG1410 TFA is a biotin labled COG1410 (HY-P2136). COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease .
    Biotin-COG1410 TFA
  • HY-169080

    Others Neurological Disease
    ABCA1 inducer 1 is a nonlipogenic ABCA1 inducer. ABCA1 inducer 1 increases ABCA1 expression, enhances apolipoprotein (APOE) lipidation and reverses multiple Alzheimer’s disease (AD) phenotypes, without increasing triglycerides in E3/4FAD mice that express human APOE 3/4 .
    ABCA1 inducer 1
  • HY-A0143S

    DGLA-d6; all-cis-8,11,14-Eicosatrienoic acid-d6

    Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Dihomo-γ-linolenic acid-d6 (DGLA-d6) is the deuterium labeled Dihomo-γ-linolenic acid. Dihomo-γ-linolenic acid (all-cis-8,11,14-Eicosatrienoic acid) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system[1][2][3].
    Dihomo-γ-linolenic acid-d6
  • HY-101903
    BMS-309403
    Maximum Cited Publications
    14 Publications Verification

    FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
    BMS-309403
  • HY-101903A
    BMS-309403 sodium
    Maximum Cited Publications
    14 Publications Verification

    FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
    BMS-309403 sodium
  • HY-100911

    Calmodulin Neurological Disease
    W-5 hydrochloride is a calmodulin antagonist. W-5 hydrochloride inhibits phosphodiesterase activation with an IC50 value of 240 µM. W-5 hydrochloride can be used as a negative control for W-7 (HY-100912) .
    W-5 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: